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Multiple diagnostic laboratory tests are frequently used in the clinical evaluation of persons with
multiple chemical sensitivity without a clear a priori hypothesis. In addition, many of these tests
are performed despite a lack of understanding of the test technical performance characteristics or
the clinical significance (test sensitivity and specificity). The result is a plethora of laboratory data
that have little clinical relevance and that can be both misleading and misused. Environ Health
Perspect 105(Suppl 2):443-444 (1997)
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As medical knowledge and technical capa-
bilities have expanded, so have our abilities
and tendencies to use laboratory tests to
evaluate the function and/or dysfunction of
human biological systems. In the practice of
medicine, the outcome ofthese changes is
an increasing reliance upon laboratory tests
to reduce the uncertainties in making clini-
cal decisions. Clinical medicine laboratory
tests are most often used for evaluating and
discriminating among alternative diagnostic
considerations. Whether an electrocardio-
gram, biopsy, radiologic evaluation, or
blood test, diagnostic tests are frequently
employed by physicians to confirm or sup-
port the clinical diagnosis formed after the
medical history and physical examination.
Laboratory tests are also utilized for provid-
ing more definitive prognostic information,
monitoring response to therapy, and for the
screening for occult disease in otherwise
healthy patients. However, unless the clini-
cian selects the appropriate tests, under-
stands the limitations of the information
provided by a test, and is knowledgeable
about the limitations ofthe test, the results
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can be misleading and potentially more
harmful than beneficial. The proper inter-
pretation oflaboratory test results requires
that the physician have a working under-
standing ofhow well the test discriminates
between patients with and without the dis-
ease and what impact a negative, positive, or
even borderline test result will have on
decision-making. This stems from the real-
ization that the predictive value ofa test
depends not only on its sensitivity and
specificity but also on the prevalence ofthe
illness in the population being tested and on
the technical performance of the test. A
technically good test is both reliable (consis-
tantly reproduceable) and valid (accurately
measures what it purports to measure
without bias).
These considerations provide a basis for
discussing certain aspects ofthe role oflab-
oratory testing of the multiple chemical
sensitivity (MCS) patient as put forth in
the papers ofRoss (1) and Ziem (2) about
their perceptions of the clinical profile of
the MCS patient. It is clear from their pre-
sentations that their view is one of MCS
advocacy. Although Ross utilized a case
presentation and Ziem reported upon a
case series of MCS patients in her clinical
practice, both researchers were effective in
highlighting many of the controversies
surrounding the clinical condition known
as multiple chemical sensitivity. These
controversies provide much ofthe basis for
this workshop. Ross and Ziem touched on
case definition, presumed etiology, diagno-
sis, and treatment, as well as invoked a
number ofthe hypothetical constructs that
have been devised to explain the MCS
phenomenology. Both authors presented
results from clinical laboratory testing that
can also be considered controversial. Ross
described a case study of a patient who
developed asthma and the symptoms of
MCS shortly after moving into a new home
that was still in the process ofbeing com-
pleted. Concomitandywith moving into the
new home the patient underwent thoracic
surgery that was complicated by a postoper-
ative mediastinal hematoma. She was
described as subsequently having repeated
episodes ofstridor and bronchospasm as
well as other symptoms in response to mul-
tiple chemical exposures and medications.
Her medical history and the report ofstri-
dor certainly raises the question ofeither
mechanical or functional upper airway
obstruction that should be further evaluated
with appropriate pulmonary function test-
ing and endoscopic examination of her
upper airway. These tests either were not
considered or not presented, yet measures of
blood volatile organic compounds (VOCs)
were included in her evaluation as indicators
ofxenobiotic contamination. However,
measures ofblood VOC levels in ambient
exposure situations do not have any known
relationship to disease. Furthermore, accu-
rately measuring blood VOC levels is tech-
nically very difficult and requires special
care both in obtaining and handling the
specimen to prevent contamination with
nonbody sources. In addition, the pharma-
cokinetics ofVOCs makes blood levels a
biomarker ofacute exposure andwould not,
even ifaccurately measured, reflect xenobi-
otic contamination. Such measures ofVOC
levels in patients who report to a physician
months to years after the exposure have
minimal prognostic or diagnostic value for
MCS patients.
In the report ofher case series ofMCS
patients, Ziem presented the results of
immune panels from two different clinical
laboratories as evidence of the potential
involvement ofthe immune system in the
pathobiology ofMCS; these assays included
lymphocyte markers, autoantibodies,
chemical antibodies, and various other
markers of immune function. There are
both technical and clinical problems with
these sets ofdata. For many ofthese assays,
the technical aspects are not well standard-
ized and their clinical significance is either
very specialized or undefined. Indeed, the
change to the second laboratory was
prompted because ofdocumented concerns
about the test reproducibility of the first
Environmental Health Perspectives - Vol 105, Supplement 2 * March 1997 443H.R. KEHRL
laboratory. In addition, the large number
of parameters tested increases the likeli-
hood ofa spurious or false positive result;
chances are that for every 20 tests, 1 will be
positive. The observation that many ofthe
tests reported as positive were borderline
supports the contention that many were
falsely positive. Further complicating the
interpretation of these test results is the
realization that the assays were performed
on an exploratory basis without an a priori
hypothesis other than the suspicion that
the immune system might be involved.
Similarly, there was no clear attempt to
relate a particular set ofsymptoms and/or
exposures to any specific alteration in func-
tion. For this type oftesting to be ofvalue
requires that the test be shown to have some
degree ofsensitivity and specificity in identi-
fying the parameter ofinterest. This would
require carefully designed clinical epidemi-
ology studies with a well defined patient
population and appropriate control group.
Probably ofmore significance and con-
troversy is the contention that the biologic
plausibility of immune system involve-
ment in the pathogenesis of MCS is sus-
pect. The lack of consistent physical
findings or laboratory evidence ofsystemic
inflammation argues against an autoim-
mune basis for MCS. Moreover, a princi-
pal characteristic ofthe immune system is
its specificity, and therefore immune sys-
tem dysfunction is unlikely to account for
the spreading phenomenon described by
MCS patients. There also is little evidence
ofimmune system dysfunction in terms of
an MCS association with autoimmune
disease, increase in opportunistic infec-
tions, increase in cancer risk, or even rela-
tionship to atopy. At best, some of these
immune markers may be identified as bio-
markers of exposure and this would also
require carefully designed studies with
rigorous attention to laboratory methods
and exposure assessment. Unfortunately, by
focusing interest on the immune system, this
and similar reports have overlooked other
components ofhost defense such as direct
irritant responses and neurogenic inflam-
mation even though they provide a poten-
tial biologic basis for components of the
MCS symptomatology.
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